Novartis Injects Itself Into Planned Rollout of EpiPen Competitor

·

·

Novartis Injects Itself Into Planned Rollout of EpiPen Competitor

Adamis Pharmaceuticals Corp. ADMP 37.50% said it agreed to sell the U.S. commercial rights for Symjepi, an epinephrine injector for the emergency treatment of allergic reactions, to Novartis AG NVS -1.76% unit Sandoz Inc. Under the exclusive agreement,
See Original Article

UHY Advisors becomes reseller of Glasswall's cybersecurity platform

New York-based accounting firm UHY Advisors has formed a strategic alliance with U.K.-based Glasswall Solutions Limited to bolster its risk advisory
See Original Article

The bad news keeps coming for MiMedx and its new auditor EY

“A financial restatement of this magnitude is a significant red flag in respect to a company's accounting quality,” Audit Analytics wrote in early June.
See Original Article

Is Century Aluminum Company (NASDAQ:CENX) Undervalued After Accounting For Its Future …

Century Aluminum Company (NASDAQ:CENX) closed yesterday at $15.62, which left some investors asking whether the high earnings potential can
See Original Article

The next big thing in PM systems

Jim McGinnis, executive vice president and general manager for medium and large firms at Wolters Kluwer Tax & Accounting North America, said,
See Original Article



Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.